<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene H69del;V70del;Y144del;N501Y;A570D;P681H;T716I;S982A;D1118H literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.H69_V70del;Y144del;N501Y;A570D;P681H;T716I;S982A;D1118H</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Six fold increase in affinity for ACE2 by the B.1.1.7 lineage vs wild type is driven by a drop in observed dissociation rate constant.<br/> (<a href="https://doi.org/10.1038/s41586-021-03412-7" class="lit_link">Collier et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus.<br/> (<a href="https://doi.org/10.1101/2021.02.05.430003" class="lit_link">Tada et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Neutralization capacity GMT of 27 subjects' sera post-infection was considerably higher (stronger) than after the second .<br/>Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed. (<a href="https://doi.org/10.1038/s41586-021-03412-7" class="lit_link">Collier et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="outcome_hazard_ratio">Outcome hazard ratio</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using primarily S-defining mutations for lineage B.1.1.7, most models of hospitalization and fatality risk ratios from consortium members show elevated ratios (~1.3-1.7x).<br/> (<a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf" class="lit_link">NERVTAG Consortium (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Danish study of the B.1.1.7 lineage shows hospital admission odds ratio of 1.63 vs other lineages. The adjusted OR was increased in all strata of age.<br/> (<a href="https://doi.org/10.2139/ssrn.3792894" class="lit_link">Bager et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> On average across 7 European countries studied, using B.1.1.7 defining mutations:.<br/>Significant shift to asymptomatic cases (27.4% vs 18.6% for non-VOC cases).  Significant shift to infection in those without pre-existing conditions (44.8% vs 89% for non-VOC cases).<br/>Significant increase in hospitalization rate (11% vs 7.5% for non-VOC cases). Significant increase in ICU rate (1.4% vs 0.6% for non-VOC cases).<br/>Significant decrease in death rate (2.0% vs vs 4.0% for non-VOC cases). (<a href="https://doi.org/10.2807/1560-7917.ES.2021.26.16.2100348" class="lit_link">Funk et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The matching-adjusted conditional odds ratio of hospitalisation was 1.58 (95% confidence interval 1.50 to 1.67) for COVID-19 patients  infected with a SGTF-associated variant [primarily B.1.1.7], compared to those infected with non-SGTF-associated variants.<br/>The effect was modified by age (p<0.001), with ORs of 0.96-1.13 below age 20 years and 1.57-1.67 in age groups 40 years or older. (<a href="https://doi.org/10.48550/arXiv.2104.05560" class="lit_link">Nyberg et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Using UK data 1 November 2020 to 14 February 2021, while correcting for misclassification of PCR test Spike Gene Target Failure (SGTF) and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with  pre-existing variants after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date.<br/>This corresponds to the absolute risk of death for a 55–69-year-old man increasing from  0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community.<br/> (<a href="https://doi.org/10.1038/s41586-021-03426-1" class="lit_link">Davies et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 341 samples collected Nov 9 to Dec 20, 2020 were sequenced from two London (UK) hospitals. <br/> 198 (58%) of 341 had B.1.1.7 infection and 143 (42%) had non-B.1.1.7 infection. No evidence was found of an association  between severe disease and death and lineage (B.1.1.7 vs non-B.1.1.7) in unadjusted analyses (prevalence ratio [PR] 0·97  [95% CI 0·72-1·31]), or in analyses adjusted for hospital, sex, age, comorbidities, and ethnicity (adjusted PR 1·02 [0·76-1·38]).<br/> (<a href="https://doi.org/10.1016/s1473-3099(21)00170-5" class="lit_link">Frampton et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> From Sept 28 to Dec 27, 2020, positive COVID-19 tests were reported by 36 920 COVID Symptom Study app users whose region was  known and who reported as healthy on app sign-up. We found no changes in reported symptoms or disease duration associated with B.1.1.7. <br/> (<a href="https://doi.org/10.1016/s2468-2667(21)00055-4" class="lit_link">Graham et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The mortality hazard ratio associated with infection with [B.1.1.7] compared with infection with previously circulating variants was  1.64 (95% confidence interval 1.32 to 2.04) in patients who tested positive for covid-19 in the community (54906 matched pairs of  participants who tested positive for SARS-CoV-2 in pillar 2 between 1 October 2020 and 29 January 2021). In this comparatively low risk  group, this represents an increase in deaths from 2.5 to 4.1 per 1000 detected cases.<br/> (<a href="https://doi.org/10.1136/bmj.n579" class="lit_link">Challen et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="trafficking">Trafficking</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> VSV pseudotype B.1.1.7 showed no significant difference in cell entry relative to wild type in 6 cell lines.<br/>Cell fusion proficiency was unchanged. (<a href="https://doi.org/10.1016/j.cell.2021.03.036" class="lit_link">Hoffman et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="transmissibility">Transmissibility</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> We estimate that this [B.1.1.17] variant has a 43–90% (range of 95% credible intervals 38–130%) higher reproduction number than preexisting variants.<br/>Data from other countries yield similar results: we estimate that R for VOC 202012/01 relative to other lineages is 55% (45–66%) higher in Denmark,  74% (66–82%) higher in Switzerland, and 59% (56–63%) higher in the United States, with consistent rates of displacement across regions within each country.<br/> (<a href="https://doi.org/10.1126/science.abg3055" class="lit_link">Davies et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other  lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load.<br/> (<a href="https://doi.org/10.1101/2021.04.16.21255459" class="lit_link">Lyngse et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> At the national level (Italy), we estimated a mean relative transmissibility of B.1.1.7 (compared to historical lineages) ranging  between 1.55 and 1.57 (with confidence intervals between 1.45 and 1.66).<br/> (<a href="https://doi.org/10.1101/2021.04.06.21254923" class="lit_link">Stefanelli et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Ontario, Feb 2021: The secondary attack rate for VOC index cases in this matched cohort was 1.31 times higher than non-VOC index cases (RR=1.31, 95%CI 1.14-1.49) (<a href="https://www.medrxiv.org/content/10.1101/2021.03.31.21254502v1" class="lit_link">Buchan et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Oslo, Norway: Within households, we find an increase in the secondary attack rate by 60% (20% 114%) compared to other variants.<br/>In general, we find a significant increase in the estimated reproduction number of 24% (95% CI 0% - 52%), or an absolute  increase of 0.19 compared to other variants.<br/> (<a href="https://doi.org/10.1101/2021.03.29.21254122" class="lit_link">Lindstrøm et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Based on ∼300,000 RT-PCR samples collected from December 6th 2020 to February 10th 2021 in Israel,  the B.1.1.7 is 45% (95% CI:20-60%) more transmissible than the wild-type strain, and become dominant in Israel within 3.5 weeks.<br/> (<a href="https://doi.org/10.1016/j.xcrm.2021.100264" class="lit_link">Munitz et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Based on 36920 COVID Symptom Study app users reported SARS-CoV-2 test positivity in late 2020, .<br/>Rt of B.1.1.7 was 1.35x (95% CI 1.02-1.69) relative to pre-existing variants. However, Rt fell below 1 during regional and  national lockdowns, even in regions with high proportions of infections with the B.1.1.7 variant.<br/> (<a href="https://doi.org/10.1016/s2468-2667(21)00055-4" class="lit_link">Graham et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees  5.2-fold against B.1.1.7 (contrast with 3.4 fold against original SARS-CoV-2).<br/> (<a href="https://doi.org/10.1101/2021.04.25.21256049" class="lit_link">Leier et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> VSV pseudotype B.1.1.7 showed 1.77-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose.<br/>Cell fusion proficiency was unchanged. (<a href="https://doi.org/10.1016/j.cell.2021.03.036" class="lit_link">Hoffman et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Lineage B.1.1.7 spike–pseudotyped VSV was tested for neutralization vs Wuhan reference genome pseudotype in 40 sera collected 7 or 21 days post-booster dose. Statistically significant change (22%) in neutralization was observed among the 26 sera from those <=55yo,  but not in the 14 sera from those >55yo. A ~20% change is not considered immunologically significant historically in influenza antibody studies. <br/> (<a href="https://doi.org/10.1126/science.abg6105" class="lit_link">Muik et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Vaccine elicited antibodies neutralized virus with the B.1.1.7 spike protein with titers similar to D614G virus. Serum specimens  from individuals vaccinated with the BNT162b2 mRNA vaccine neutralized D614G virus with titers that were on average 7-fold greater than convalescent sera.<br/> (<a href="https://doi.org/10.1101/2021.02.05.430003" class="lit_link">Tada et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 20/29 sera after the first dose of Pfizer showed an average reduction in neutralization titres against the B.1.1.7 variant of 3.2 ± 5.7.<br/>After the second dose, the GMT was markedly increased compared with the first-dose titres, with a fold change of 1.9 ± 0.9 (mean ± s.d.). Neutralization GMT of 27 subjects post-infection was considerably higher (stronger) than after the second Pfizer dose, and 4.5x drop in B.1.1.7 neutralization was observed.<br/> (<a href="https://doi.org/10.1038/s41586-021-03412-7" class="lit_link">Collier et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="viral_load">Viral load</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> We found that the British variant (clade B.1.1.7), compared to an ancestral SARS-CoV-2 clade B virus, produced higher  levels of infectious virus late in infection and had a higher replicative fitness in human airway, alveolar and intestinal organoid models.<br/> (<a href="https://doi.org/10.1101/2021.05.03.441080" class="lit_link">Lamers et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> This study reveals that B.1.1.7 SARS-CoV-2 variant is a slower-growing virus than parental B.1. Further, a higher replication along with reduced infectious viral titer was hypothesized to be linked to higher transmission with reduced pathogenicity. <br/> (<a href="https://doi.org/10.1101/2021.04.30.442222" class="lit_link">Nyayanit et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> In a study of 1260 ICU subjects, viral load distributions (collected within 48h of admission) were elevated in  both seropositive and seronegative subjects infected with B.1.1.7 ("UK variant"). <br/> PG: The PANGO tool defining Spike variants for B.1.1.7 are listed here, whereas the paper only used a test for D1118H.<br/> (<a href="https://doi.org/10.1101/2021.02.24.21251989" class="lit_link">Ratcliff et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Using lack of S probe detection as a proxy for B.1.1.7 status, 275 putative B.1.1.7 samples and 390 "wild type" SARS-CoV-2 positive samples in Wales were compared for Ct values, suggesting ~12-fold increase (~3.5 Ct decrease) in viral load for B.1.1.7 samples.<br/> (<a href="https://doi.org/10.1101/2021.04.02.21254832" class="lit_link">Couzens et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The 249 B.1.1.7 (a.k.a. N501Y.V1) variant cases in three Paris hospital labs had a ~10-fold viral load increase  (~3.3 Ct drop in N gene probe) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). <br/> PG: BUT there is a discrepancy in drop between the ORF1ab and N probes, with the former suggesting only a 2-fold drop,  consistent with the drop observed in B.1.351. This might indicate higher subgenomic RNA content in B.1.1.7 skewing the change.<br/> (<a href="https://doi.org/10.1101/2021.03.21.21253498" class="lit_link">Teyssou et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> B.1.1.7 samples showed average Ct cycle threshold of 21.9 vs 23 for wildtype (i.e. ~2x higher viral load) comparing 37758 and 22535 samples respectively.<br/> (<a href="https://doi.org/10.1101/2021.03.19.21253971" class="lit_link">Roquebert et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The median Ct value of RT-qPCR tests of the N-gene target in the Daxing B.1.1.7 group was significantly lower than the Shunyi B.1.470 group (P=0.036).<br/> (<a href="https://doi.org/10.1101/2021.05.04.21256655" class="lit_link">Song et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
